arrow
L

Lígia A. Pinto

London School of Hygiene and Tropical Medicine
H指数:48
被引数:8,034

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effect of malaria parasitaemia on antibody responses to single-dose and two-dose HPV vaccination: results from the DoRIS dose-reduction immunogenicity trial in Tanzanian girls

疟疾寄生虫血症对单剂量和双剂量HPV疫苗接种后抗体反应的影响:来自坦桑尼亚女孩DoRIS减量免疫原性试验的结果

Vaccine
IF3.5
2026-06-010
OAAI
Neutralizing antibody responses to the primary series of a COVID-19 mRNA vaccine in the cancer cohort under active treatment

癌症患者队列在接受积极治疗期间,对COVID-19 mRNA疫苗基础免疫程序的中和抗体应答

2025-12-310
PRE
Noninferiority of One HPV Vaccine Dose to Two Doses
2025-12-018
PRE
Memory B-cells elicited by different HPV vaccine regimens in the DoRIS randomised controlled trial

DoRIS随机对照试验中,由不同HPV疫苗方案诱导的记忆B细胞

2025-11-280
OAAI
Humoral immune responses to the second dose of a COVID-19 mRNA vaccine in cancer patients undergoing treatment

癌症治疗患者对COVID-19 mRNA疫苗第二剂次的体液免疫应答

2025-10-140
OAAI
Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9–14 years compared with three doses of quadrivalent HPV vaccine in women aged 18–25 years in Costa Rica (PRIMAVERA): a non-randomised, open-label, immunobridging, non-inferiority trial

人乳头瘤病毒(HPV)16型和18型抗体浓度:在哥斯达黎加(PRIMAVERA)的9~14岁女孩中,接种一剂双价HPV疫苗后的抗体浓度与在18~25岁女性中接种三剂四价HPV疫苗后的抗体浓度比较——一项非随机、开放标签、免疫桥接、非劣效性试验

2025-07-160
PREAI
Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9–14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trial

在加纳和孟加拉国9-14岁女孩中,由大肠杆菌生产的二价人乳头瘤病毒疫苗(Cecolin)的免疫原性和安全性:一项随机、对照、开放标签、非劣效性、III期试验

2025-03-190
OAAI
Coronavirus Disease 2019 (COVID-19) Real World Data Infrastructure: A Big-Data Resource for Study of the Impact of COVID-19 in Patient Populations With Immunocompromising Conditions
2025-01-230
OA
Immune profile diversity is achieved with synthetic TLR4 agonists combined with the RG1-VLP vaccine in mice

通过合成TLR4激动剂与RG1-VLP疫苗联合使用,可在小鼠中实现免疫谱系多样性。

VACCINE
IF3.5
2025-01-011
OAAI
Frameshift mutations in peripheral blood as a biomarker for surveillance of Lynch syndrome
2024-03-111
OA